Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T65864 Target Info
Target Name Stress-activated protein kinase 2a (p38 alpha)
Synonyms SAPK2A; P38 mitogen activatedprotein kinase; P38 Mitogen-activatedprotein kinase alpha; Mitogen-activated protein kinase p38 alpha; Mitogen-activated protein kinase 14; MXI2; MAX-interacting protein 2; MAPK 14; MAP kinase p38alpha; MAP kinase p38 alpha; MAP kinase MXI2; MAP kinase 14; Cytokine suppressive anti-inflammatory drug-binding protein; Cytokine suppressive anti-inflammatory drug binding protein; CSPB1; CSBP2; CSBP1; CSBP; CSAID-binding protein; CSAID binding protein; CRK1
Target Type Clinical trial Target
Gene Name MAPK14
Biochemical Class Kinase
UniProt ID
MK14_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
World Intellectual Property Organization (WIPO)
Patent ID WO2012083092
Title Bi-Dentate Compounds As Kinase Inhibitors.
Abstract The present disclosure provides compound having the general structure A or pharmaceutically acceptable salts thereof: Het-L-P (A) wherein Het is an aromatic moiety comprising a heterocyclic structure mimicking ATP, P is a docking site derived peptide or a docking site peptide rnimetic, and L is a linking moiety, wherein L links the ATP mimetic to the docking site peptide moiety. The compounds having the general structure A can serve as inhibitors of kinases, such as the kinases JNK, Erk and p38.
Applicant(s) Sanford-Burnham Medical Research Institute
Representative Drug(s) D0Q8CR Drug Info IC50 = 190 nM Click to Show More [1]
2 D08OJQ Drug Info IC50 > 5000 nM [1]
3 D0G7LB Drug Info IC50 > 10000 nM [1]
Patent ID WO2011071491
Title Isotopologues of 4-[9-(Tetrahydro-Furan-3-Yl)-8-(2, 4, 6- Trifluoro-Phenylamino)-9H-Purin-2-Ylamino]-Cyclohexan-1-Ol.
Abstract Provided herein are isotopologues of Compound 1, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provided.
Applicant(s) Signal Pharmaceuticals
Representative Drug(s) D06JRV Drug Info IC50 = 3400 nM [1]
Patent ID WO2010069833
Title Pyrimidin- 2 -Ylamino Derivatives and Their Use To Treat Inflammation.
Abstract Compounds of formula (I) modulate JNK wherein X1 and X2 are each simultaneously N or CH; X3 is CH-R2 or N-SO2R, where R is lower alkyl; R1 is aryl or heteroaryl, substituted with 0-3 lower alkyl radicals; R2 is formula (II), where R3 is H, lower acyl, or an amino acid, or a pharmaceutically acceptable salt thereof.
Applicant(s) F. Hoffmann-La Roche Ag
Representative Drug(s) D0H4HD Drug Info IC50 < 10000 nM [1]
Patent ID WO2008028860
Title Benzotriazole Kinase Modulators.
Abstract The invention is concerned with novel benzotriazole derivatives of Formula (I) Wherein R, R1, R2, R3, and m are as defined in the description and the claims, as well as physiologically acceptable salts thereof. These compounds are JNK and CDK modulators.
Applicant(s) F. Hoffmann-La Roche Ag
Representative Drug(s) D0H4HD Drug Info IC50 < 10000 nM [1]
Patent ID WO2001027268
Title Cell-Permeable Peptide Inhibitors of The Jnk Signal Transduction Pathway.
Abstract The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.
Applicant(s) University of Lausanne
Representative Drug(s) D03JFK Drug Info N.A. [1]
References  Top
REF 1 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.